Pierre Fabre

Executive Summary

Pierre Fabre is a French pharmaceutical and dermo-cosmetic group founded in 1962, with a unique dual expertise in prescription drugs and dermo-cosmetics. The company focuses on oncology, chronic diseases, and everyday ailments, offering a holistic approach to care. Majority-owned by a public benefit foundation and its employees, Pierre Fabre emphasizes social and environmental responsibility. Despite being a private company, it maintains a strong global presence, particularly in dermatology and oncology. Its stage is listed as pre-clinical, but as an established player, it likely has a diverse pipeline of early-stage to marketed products. The company's integrated model allows it to leverage synergies between its pharmaceutical and cosmetic divisions, driving innovation in areas such as antibodies, biologics, and small molecules.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for novel oncology antibody-drug conjugate70% success
• Q2 2026Launch of new Avène dermo-cosmetic product line in US market80% success
• Q4 2026Partnership or licensing deal for biologics platform60% success